



Pfizer sponsored satellite symposia June 9<sup>th</sup> 2026:

## **Data-driven care, long-term impact: improving ATTR-CM patients' outcomes in Israel**

We invite you to join an engaging scientific session focusing on data-driven care and long-term impact in the management of Amyloid transthyretin cardiomyopathy (ATTR-CM). The program will address key challenges in diagnosis, disease monitoring, and therapeutic optimization, with expert perspectives from leading cardiologists in Israel and abroad, aiming to support informed clinical decision-making and improve patient outcomes.

### **Speakers:**

- **Prof. Michael Arad, Sheba Medical Center, Israel** (Moderator) – Opening remarks, overview of key diagnostic challenges, and the importance of managing arrhythmias, thromboembolic events, and heart failure
- **Prof. Pablo Garcia, Hospital Universitario Puerta de Hierro, Madrid, Spain** (Virtual from Madrid) – **Beyond Diagnosis: Monitoring Progression in ATTR-CM**, what should be tracked and what data is currently available
- **Dr. Osnat Yitzhaki, Beilinson Hospital, Rabin Medical Center, Israel** – **Optimizing Transthyretin Heart Failure Therapies**, concise review of current therapy mechanisms and an introduction to non-amyloid therapy
- Expert panel discussion – Topics prepared by Prof. Arad and audience Q&A



### Detailed Timetable:

<b>Time</b>	<b>Topic</b>	<b>Speaker</b>
13:00-13:05	Opening remarks, overview of diagnostic challenges and management domains	Prof. Michael Arad
13:05-13:25	Beyond Diagnosis: Monitoring Progression in ATTR-CM	Prof. Pablo Garcia
13:25-13:45	Optimizing Transthyretin Heart Failure Therapies	Dr. Osnat Yitzhaki
13:45-14:00	Expert panel discussion Q&A	All

Note: The wording is subject to minor revisions.